Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

Bern, 02.07.2021 - Up to 29 June 2021, Swissmedic evaluated 3,419 reports on suspected adverse drug reactions (ADR) to COVID-19 vaccinations in Switzerland. The majority of the reports involved more than one reaction. At 2,125 (62.2 %), most of the reports were classified as not serious, while 1,294 (37.8 %) reports were classified as serious.

Most of the reports were submitted by medical professionals, while a relatively large number (632, or 18.5 %) came directly from those affected, i.e. the patients. The average age of those affected was 62 years (range 16–101), with 30.3% aged 75 or over. In the cases classified as serious, the average age was 65.2 years, and for reports temporally linked to a death it was 80.6 years.

The majority of the reports concerned women (67.4%). Men were affected in 29.4 % of cases, and there were a few cases (3.2 %) where no gender was specified. 1,377 (40.3 %) reports involve Pfizer/BioNTech’s Comirnaty®, while 1,983 (58 %) are associated with Moderna's COVID-19 vaccine. In 59 (1.7 %) cases, the vaccine was not specified.

The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on

Address for enquiries

Media Unit

+41 58 462 02 76


Swiss Agency for Therapeutic Products